RU2636456C2 - Гликозилированный полипептид и содержащая его фармацевтическая композиция - Google Patents

Гликозилированный полипептид и содержащая его фармацевтическая композиция Download PDF

Info

Publication number
RU2636456C2
RU2636456C2 RU2014116550A RU2014116550A RU2636456C2 RU 2636456 C2 RU2636456 C2 RU 2636456C2 RU 2014116550 A RU2014116550 A RU 2014116550A RU 2014116550 A RU2014116550 A RU 2014116550A RU 2636456 C2 RU2636456 C2 RU 2636456C2
Authority
RU
Russia
Prior art keywords
fmoc
sugar chain
polypeptide
solution
glycosylated
Prior art date
Application number
RU2014116550A
Other languages
English (en)
Russian (ru)
Other versions
RU2014116550A (ru
Inventor
Идзуми САКАМОТО
Кадзухиро ФУКАЭ
Кацунари ТЭДЗУКА
Кэйсукэ ТАДЗУРУ
Масатоси МАЭДА
Ясухиро КАДЗИХАРА
Такаси ЦУДЗИ
Original Assignee
Глитек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глитек, Инк. filed Critical Глитек, Инк.
Publication of RU2014116550A publication Critical patent/RU2014116550A/ru
Application granted granted Critical
Publication of RU2636456C2 publication Critical patent/RU2636456C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2014116550A 2011-10-01 2012-09-28 Гликозилированный полипептид и содержащая его фармацевтическая композиция RU2636456C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011-218793 2011-10-01
JP2011218793 2011-10-01
PCT/JP2012/075262 WO2013047846A1 (ja) 2011-10-01 2012-09-28 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物

Publications (2)

Publication Number Publication Date
RU2014116550A RU2014116550A (ru) 2015-10-27
RU2636456C2 true RU2636456C2 (ru) 2017-11-23

Family

ID=47995870

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014116550A RU2636456C2 (ru) 2011-10-01 2012-09-28 Гликозилированный полипептид и содержащая его фармацевтическая композиция

Country Status (16)

Country Link
US (1) US10358470B2 (https=)
EP (1) EP2762489B1 (https=)
JP (1) JP6153470B2 (https=)
KR (1) KR101979045B1 (https=)
CN (2) CN109134642A (https=)
AU (1) AU2012317325B2 (https=)
BR (1) BR112014007766B1 (https=)
CA (1) CA2850469C (https=)
DK (1) DK2762489T3 (https=)
IN (1) IN2014CN02982A (https=)
MY (1) MY168902A (https=)
PH (1) PH12014500694B1 (https=)
RU (1) RU2636456C2 (https=)
SG (2) SG11201401071YA (https=)
TW (1) TWI633115B (https=)
WO (1) WO2013047846A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2762489T3 (en) 2011-10-01 2018-07-02 Glytech Inc GLYCOSYLED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
SG11201507769SA (en) * 2013-03-29 2015-10-29 Glytech Inc Polypeptide having sialylated sugar chains attached thereto
CN114685645B (zh) * 2020-12-30 2025-03-21 深圳翰宇药业股份有限公司 一种索玛鲁肽的合成方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
WO2003075944A2 (en) * 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
EA009289B1 (ru) * 2002-09-27 2007-12-28 Байоджен Айдек Ма Инк. ЛЕЧЕНИЕ ХРОНИЧЕСКОЙ ВОСПАЛИТЕЛЬНОЙ ДЕМИЕЛИНИЗИРУЮЩЕЙ ПОЛИНЕВРОПАТИИ С ИСПОЛЬЗОВАНИЕМ β-ИНТЕРФЕРОНА
US20080003202A1 (en) * 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
RU2007103479A (ru) * 2004-08-09 2008-09-20 Элиоз Байофарма, Инк. (Сша/Сша) (Us) Синтетические варианты гипергликолизованного протеазо-резистивного полипептида, пероральные композиции и способы применения таких вариантов
WO2010015722A1 (en) * 2008-08-08 2010-02-11 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
JP2001507215A (ja) 1997-01-16 2001-06-05 サイテル コーポレイション 組換え糖タンパク質のインビトロでの実用的なシアリル化
DE19717864C2 (de) 1997-04-23 2001-05-17 Fraunhofer Ges Forschung Humanes rekombinantes Interferon-beta, Verfahren zu seiner Herstellung und seine Verwendung
EE05214B1 (et) * 1998-04-28 2009-10-15 Applied Research Systems ARS Holding N.V. Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
US6514729B1 (en) * 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
EP1240327B1 (en) * 1999-12-08 2008-02-06 Amgen Inc., Interferon-like molecules and uses thereof
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
KR20030057529A (ko) 2000-09-08 2003-07-04 그리폰 테라퓨틱스, 인코포레이티드 합성 적혈구생성 자극 단백질
WO2002074806A2 (en) 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
BR0208041A (pt) 2001-03-15 2004-02-25 Merck Patent Gmbh Interferon beta modificado com imunogenicidade reduzida
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
ES2411007T3 (es) * 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
AU2002358181A1 (en) 2001-12-11 2003-07-09 Aventis Pasteur Mutated hiv tat
US7943763B2 (en) 2002-07-05 2011-05-17 Otsuka Chemical Holdings Co., Ltd. Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides
AU2003254641A1 (en) 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
EP1581631A4 (en) 2002-10-01 2007-09-05 Xencor Inc INTERFERON VARIANTS HAVING IMPROVED PROPERTIES
KR100876518B1 (ko) 2002-12-26 2008-12-31 오츠카 가가쿠 가부시키가이샤 당사슬 아스파라긴 유도체 및 그의 제조방법
AU2004266969B2 (en) 2003-08-25 2010-02-25 Taniguchi, Tadatsugu Interferon-beta composite
US20090214472A1 (en) 2004-03-01 2009-08-27 Enzon Pharmaceuticals Inc. Interferon-beta polymer conjugates
WO2006020580A2 (en) 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
KR100781666B1 (ko) 2004-11-02 2007-12-03 신영기 인간 인터페론-베타 변이체
WO2007022799A1 (en) * 2005-08-26 2007-03-01 Ares Trading S.A. Process for the preparation of glycosylated interferon beta
US20080096819A1 (en) 2006-05-02 2008-04-24 Allozyne, Inc. Amino acid substituted molecules
KR20100049032A (ko) * 2007-06-19 2010-05-11 오츠카 가가쿠 가부시키가이샤 당사슬 부가 ｇｌｐ―１ 펩티드
CA2694542C (en) 2007-07-31 2017-08-29 Otsuka Chemical Co., Ltd. Method for producing peptide
JP2009242372A (ja) 2008-03-11 2009-10-22 Yokohama City Univ 均一な糖鎖構造を有するエリスロポエチン誘導体
US8765669B2 (en) 2008-06-17 2014-07-01 Glytech, Inc. Glycosylated GLP-1 peptide
HUE037238T2 (hu) * 2008-08-19 2018-08-28 Glytech Inc Glikoprotein elõállítási eljárás és screening eljárás
WO2012051615A1 (en) 2010-10-15 2012-04-19 Transgenrx, Inc. Novel vectors for production of glycosylated interferon
RU2586524C2 (ru) 2011-03-10 2016-06-10 Глитек, Инк. Способ получения гликопептида, имеющего сиалированную сахарную цепь, и способ получения производного сиалилгликоаспарагина
WO2013002330A1 (ja) 2011-06-29 2013-01-03 協和発酵キリン株式会社 たん白質の精製方法
DK2762489T3 (en) 2011-10-01 2018-07-02 Glytech Inc GLYCOSYLED POLYPEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023472A2 (en) * 1998-10-16 2000-04-27 Biogen, Inc. Interferon-beta fusion proteins and uses
WO2003075944A2 (en) * 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
EA009289B1 (ru) * 2002-09-27 2007-12-28 Байоджен Айдек Ма Инк. ЛЕЧЕНИЕ ХРОНИЧЕСКОЙ ВОСПАЛИТЕЛЬНОЙ ДЕМИЕЛИНИЗИРУЮЩЕЙ ПОЛИНЕВРОПАТИИ С ИСПОЛЬЗОВАНИЕМ β-ИНТЕРФЕРОНА
RU2007103479A (ru) * 2004-08-09 2008-09-20 Элиоз Байофарма, Инк. (Сша/Сша) (Us) Синтетические варианты гипергликолизованного протеазо-резистивного полипептида, пероральные композиции и способы применения таких вариантов
US20080003202A1 (en) * 2006-03-28 2008-01-03 Thierry Guyon Modified interferon-beta (IFN-beta) polypeptides
WO2010015722A1 (en) * 2008-08-08 2010-02-11 Vib Vzw Cells producing glycoproteins having altered glycosylation patterns and methods and use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GREENE T.W. et al. Protective groups in organic synthesis, 2-е издание, John Wiley & Sons, Inc, Canada, 1991, p.473. *
GREENE T.W. et al. Protective groups in organic synthesis, 2-е издание, John Wiley & Sons, Inc, Canada, 1991, p.473. RUNKEL L. et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β), Pharmaceutical research, 1998, v.15, n. 4, p. 641-646. *
KARPUSAS M. et al. The crystal structure of human interferon beta at 2.2-A resolution, Proc. Natl. Acad. Sci. U.S.A., 1997, v. 94, n. 22, p. 11813-11818. *
RUNKEL L. et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-β (IFN-β), Pharmaceutical research, 1998, v.15, n. 4, p. 641-646. *

Also Published As

Publication number Publication date
CA2850469A1 (en) 2013-04-04
DK2762489T3 (en) 2018-07-02
TW201321404A (zh) 2013-06-01
SG11201401071YA (en) 2014-08-28
CN104080803A (zh) 2014-10-01
TWI633115B (zh) 2018-08-21
AU2012317325B2 (en) 2016-10-06
AU2012317325A1 (en) 2014-04-17
BR112014007766A2 (pt) 2017-04-04
EP2762489B1 (en) 2018-03-28
IN2014CN02982A (https=) 2015-07-03
SG10201602076QA (en) 2016-04-28
CA2850469C (en) 2020-07-07
PH12014500694A1 (en) 2014-05-12
MY168902A (en) 2018-12-04
EP2762489A9 (en) 2015-02-11
KR101979045B1 (ko) 2019-05-15
PH12014500694B1 (en) 2020-01-31
EP2762489A1 (en) 2014-08-06
WO2013047846A1 (ja) 2013-04-04
CN104080803B (zh) 2020-08-04
US20140369964A1 (en) 2014-12-18
KR20140095051A (ko) 2014-07-31
JPWO2013047846A1 (ja) 2015-03-30
RU2014116550A (ru) 2015-10-27
US10358470B2 (en) 2019-07-23
JP6153470B2 (ja) 2017-06-28
EP2762489A4 (en) 2015-05-06
BR112014007766B1 (pt) 2022-05-10
CN109134642A (zh) 2019-01-04

Similar Documents

Publication Publication Date Title
AU2012226981B2 (en) Method for producing glycopeptide having sialyl sugar chain, sialyl sugar chain-added amino acid derivative to be used in same, and glycopeptide
CN104936613B (zh) 糖链加成连接子、含有糖链加成连接子与生理活性物质的化合物或其盐、以及其制造方法
RU2636456C2 (ru) Гликозилированный полипептид и содержащая его фармацевтическая композиция
US20120114595A1 (en) Sugar chain-added ailim extracellular domain and method for producing same
EP2982686B1 (en) Polypeptide having sialylated sugar chains attached thereto